Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Study of NB004 As Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: NB004 tablets
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Ningbo Newbay Technology Development Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT05036291
- Locations
- 🇺🇸
LSU-LCMC Health Cancer Center, New Orleans, Louisiana, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳National Cheng Kung University Hospital（NCKUH）, Tainan, Taiwan, China
A Study of NB003 in Patients with Advanced Malignancies
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Ningbo Newbay Technology Development Co., Ltd
- Target Recruit Count
- 258
- Registration Number
- NCT04936178
- Locations
- 🇺🇸
Standford University, Stanford, California, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
News
No news found